FDA Approves Tirzepatide as First Treatment for Obstructive Sleep Apnea and Obesity

Published Date: 26 Dec 2024

Adults with obstructive sleep apnea who receivied tirzepatide achieved an average of up to 20% weight loss and experienced at least 25 fewer breathing interruptions for each hour slept.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot